Project Grant R01HL188605
Award Date 8/15/26
Completion Date 4/30/31
Dollars Obligated $678K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $1,561,052 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate pulmonary ionocyte function and development using human induced pluripotent stem cell-derived airway epithelium. Performance runs through June 30, 2030, in Boston, Massachusetts. The project addresses gaps in understanding how pulmonary ionocytes—rare airway cells marked by FOXI1 and ASCL3 expression and...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $599,466 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research examining the cellular and molecular mechanisms driving submucosal gland hypertrophy in chronic lung diseases including asthma, COPD, and cystic fibrosis. The funded research will identify fundamental pathways responsible for pathological gland enlargement by defining key cell-cell interactions and signaling...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $222,750 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how innate lymphoid cell memory formed during neonatal lung injury contributes to chronic obstructive pulmonary disease development in adulthood. The project, titled "Trained Immunity in Group 2 Innate Lymphoid Cells Links Neonatal to Adult Chronic Lung...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $712,630 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate functional heterogeneity of alveoli and early responses to airborne agents. The recipient will develop and apply the Crystal Ribcage, a novel intravital imaging platform, to visualize real-time, high-resolution dynamics of the intact, ventilating lung. The research will define the anatomy, physiology,...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $740,400 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanistic role of macrophages in idiopathic pulmonary fibrosis and develop therapeutic targeting strategies. The research examines monocyte-derived alveolar macrophages (MO-AMs) in lung fibrosis pathogenesis, with focus on TREM2 receptor signaling and its regulation by sphingomyelin and...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $766,557 for a Project Grant (R01HL188011) on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into bronchiolization—the takeover of alveoli by airway cell types—a hallmark of interstitial lung diseases including idiopathic pulmonary fibrosis. The project uses CRISPR/Cas9 genome editing to generate mouse models carrying patient mutations in...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 2, 2026, to support research on the role of subpleural fibroblasts in pulmonary fibrosis progression. The funded research investigates idiopathic pulmonary fibrosis (IPF), which begins with scar tissue buildup at the lung edges and advances centrally. The project applies lineage tracing, mouse modeling, and...
- The National Heart, Lung, and Blood Institute awarded Florida International University $777,999 on June 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on airway epithelial defense mechanisms in combating STAT3-deficiency-related lung infections. The project investigates how downregulated STAT3 expression increases susceptibility to recurrent infections, particularly pneumonia and multidrug-resistant Pseudomonas aeruginosa, with focus on airway...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $917,304 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular and molecular coordination of alveolar regeneration. The award supports research into how epithelial, endothelial, and mesenchymal cells coordinate repair of alveolar structures damaged by infection, environmental toxins, hyperoxia, or barotrauma. The project examines...